Karyopharm Therapeutics Financial Overview
Karyopharm Therapeutics's market cap is currently $118.33M. The company's EPS TTM is $-3.82; its P/E ratio is -0.50; Karyopharm Therapeutics is scheduled to report earnings on November 3, 2025, and the estimated EPS forecast is $-2.08. See an overview of income statement, balance sheet, and cash flow financials.
